GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » Institutional Ownership

Atossa Therapeutics (FRA:YAG2) Institutional Ownership : 18.10% (As of Apr. 24, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Atossa Therapeutics's institutional ownership is 18.10%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Atossa Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Atossa Therapeutics's Float Percentage Of Total Shares Outstanding is 99.96%.


Atossa Therapeutics Institutional Ownership Historical Data

The historical data trend for Atossa Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Institutional Ownership Chart

Atossa Therapeutics Historical Data

The historical data trend for Atossa Therapeutics can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 15.35 17.41 17.39 18.73 18.68 18.92 18.84 18.61 18.42 18.10

Atossa Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Atossa Therapeutics Business Description

Traded in Other Exchanges
Address
10202 Fifth Avenue NE, Suite 200, Seattle, WA, USA, 98125
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Headlines

No Headlines